Treatment with alendronate prevents fractures in women at highest risk: Results from the fracture intervention trial

Archives of Internal Medicine

Volumn 157, Issue 22, 1997, Pages 2617-2624

  Ensrud, Kristine E ^a   Black, Dennis M ^b   Palermo, Lisa ^b   Bauer, Douglas C ^b   Barrett Connor, Elisabeth ^b   Quandt, Sara A ^b   Thompson, Desmond E ^b   Karpf, David B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE RADIOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 0030716177     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.22.2617     Document Type: Article

References (42)

1. Ray NF, Chan JK, Thaemer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
2. WHO Study Group on Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva, Switzerland: World Health Organization; 1994. Technical report series 843.
3. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919-923.
4. Wasnich RD, Davis JW, Ross PD. Spine fracture risk is predicted by non-spine fractures. Osteoporos Int. 1994;4:1-5.
5. Black D, Cummings S, Genant H, Nevitt M, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res. 1992;7:633-638.
6. Kotowicz MA, Melton LJ, Cooper C, Atkinson EJ, O'Fallon WM, Riggs BL. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res. 1994;9:599-605.
7. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-773.
8. Kanis JA. Treatment of osteoporosis in elderly women. Am J Med. 1995;98 (suppl 2A):S60-S66.
9. Resnick NM, Greenspan SL. Senile osteoporosis reconsidered. JAMA. 1989;261:1025-1029.
10. Sambrook PN. The treatment of postmenopausal osteoporosis. N Engl J Med. 1995;333:1495-1496.
11. Insogna K. Osteoporosis and aging: the continuing crisis. Aging Clin Exp Res. 1994;6:65-67.
12. Elton RD. Geriatric medicine. BMJ. 1996;312:561-563.
13. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
14. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR, for the Fracture Intervention Trial Research Group. Design of the Fracture Intervention Trial. Osteoporos Int. 1993;3(suppl):S29-S39.
15. Liberman UA, Weiss SR, Broil J, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
16. Cummings SR, Block G, McHenry K, Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol. 1987;126:796-802.
17. National Osteoporosis Foundation Working Group on Vertebral Fractures. Assessing vertebral fractures: a report by the National Osteoporosis Working Group on Vertebral Fractures. J Bone Miner Res. 1995;10:518-523.
18. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
19. Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129:1000-1011.
20. Black DM, Palermo L, Nevitt MC, et al. Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res. 1995;10:890-902.
21. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984.
22. Rajkumar SV, Sampathkumar P, Gustafson AB. Number needed to treat is a simple measure of treatment efficacy for clinicians. J Gen Intern Med. 1996;11:357-359.
23. Ensrud KE, Palermo L, Black DM, et al. Hip and calcaneal bone loss increase with advancing age: longitudinal results from the Study of Osteoporotic Fractures. J Bone Miner Res. 1995;10:1778-1787.
24. Jones G, Nguyen T, Sambrook P, Kelly PJ, Eisman JA. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo Osteoporosis Epidemiology Study. BMJ. 1994;309:691-695.
25. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-1642.
26. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med. 1996;124:400-406.
27. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993:341:11-13.
28. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-1146.
29. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: The Framingham Study. N Engl J Med. 1987;317:1169-1174.
30. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
31. Storm T, Thamsborg G, Steiniche T, Genant H, Sorensen OL. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990;322:1265-1271.
32. Watts NB, Harris ST, Genant HK, et al. Intermittant cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73-79.
33. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ. 1992;305:556-561.
34. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med. 1995;123:401-408.
35. Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992;326:357-362.
36. Ott SM, Chestnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989;110:267-274.
37. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med. 1990;113:649-655.
38. Chestnut CH. Osteoporosis and its treatment. N Engl J Med. 1992;326:406-407.
39. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med. 1992;327:620-627.
40. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:801-805.
41. Black DM. Why elderly women should be screened and treated to prevent osteoporosis. Am J Med. 1995;98(suppl 2A):S67-S75.
42. Yusef S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93-98.